Day: January 31, 2024

Interim Results: 1 May 2023 – 31 October 2023

Written by Customer Service on January 31, 2024. Posted in Public Companies.

Vast Resources plc / Ticker: VAST / Index: AIM / Sector: Mining 31 January 2024 Vast Resources plc(‘Vast’ or the ‘Company’) Interim Results: 1 May 2023 – 31 October 2023 Vast Resources plc, the AIM-listed mining company, is pleased to announce that it has released its unaudited interim report and financial results for period from 1 May 2023 to 31 October 2023. The report can be found on the Company’s website at the following address: https://www.vastplc.com/investor-information/document-downloads Market Abuse Regulation (MAR) Disclosure Certain information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 (“UK MAR”) until the release of this...

Trial mining license at Coringa renewed for a further three years

Written by Customer Service on January 31, 2024. Posted in Public Companies.

Trial mining license at Coringa renewed for a further three years. Serabi Gold plc (“Serabi” or the “Company”) (AIM: SRB, TSX: SBI), is pleased to announce a three year renewal of the trial mining licence for its wholly owned Coringa mine (“Coringa”). HIGHLIGHTSThe National Mining Agency (ANM) has issued a renewal of the Company’s trial mining licence (“GU”) for Coringa for an additional three years, demonstrating continued stakeholder support for Coringa. The GU permits the transport of up to 50,000 tonnes of ore per annum from Coringa, to be processed at the Palito Complex. The environmental agency Secretaria de Estado de Meio Ambiente e Sustentabilidade (“SEMAS”) is continuing its analysis of the company’s application for the Installation Licence for Coringa but has confirmed that the Company’s Trial Mining Operating Licence...

Corbion management presents strategic development update on ‘Advance 2025’

Written by Customer Service on January 31, 2024. Posted in Earnings Releases And Operating Results.

During its Capital Markets Update for analysts and investors in Amsterdam today, Corbion management will present a review of the ‘Advance 2025’ strategy development and introduce updated targets for the 2024-2025 period. Key highlightsKey financial metrics for 2023 in line with guidance1 Emulsifier business divested (closing anticipated in Q2) EBITDA growth rate outlook for ‘24/’25 reconfirmed Restructuring program in place to deliver significant Free Cash Flow in ‘24/’25 (> € 125 million cum) Simplified business structure (two Business Units) Algae roadmap: Increased value creation potential at existing production facility (€ 200 million sales by 2028) Committed to PLA journey with focus on a differentiated strategy Biomedical polymers: Goal to double sales (> €100 million) in 5 years with limited investmentOlivier Rigaud, CEO of...

Borregaard ASA: EBITDA1 of NOK 327 million in the 4th quarter

Written by Customer Service on January 31, 2024. Posted in Earnings Releases And Operating Results.

Borregaard’s operating revenues were NOK 1,605 million (NOK 1,770 million)2 in the 4th quarter of 2023. EBITDA1 was NOK 327 million (NOK 364 million). The result in BioSolutions improved while BioMaterials’ and Fine Chemicals’ results were lower compared with the 4th quarter of 2022. Operational issues at the Sarpsborg site and lower demand for and sales of biovanillin had a negative impact in the 4th quarter of approximately NOK 80 million. In BioSolutions, reduced energy costs were partly offset by reduced sales volume and cost inflation in general. The reduced result in BioMaterials was mainly due to the operational issues at the Sarpsborg site. In Fine Chemicals, lower production volume and lower sales prices in fine chemical intermediates had a negative impact on EBITDA1 compared with the 4th quarter of 2022. The net currency effects...

Geneva Court Grants Temporary Moratorium to ObsEva

Written by Customer Service on January 31, 2024. Posted in Public Companies.

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss ExchangeGeneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s health, today announced that it was granted a temporary moratorium (sursis provisoire) by the competent court in Geneva, Switzerland. The Tribunal de première instance of Geneva granted the requested moratorium for a period of four months ending 29 May 2024 and appointed a commissioner (commissaire) to supervise the company’s activities during the process. The moratorium limits the ability of ObsEva’s creditors to enforce their claims against the company while it evaluates the possibility of a restructuring or orderly liquidation. ObsEva had requested to be granted a temporary moratorium in December 2023 to enable the company...

Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.

Written by Customer Service on January 31, 2024. Posted in Public Companies.

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 31, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the company has entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, ADSs having an aggregate offering price of up to $2.1 million through H.C. Wainwright as its sales agent. The issuance and sale, if any, of the ADSs by the Company under the ATM Agreement will be made pursuant to the Company’s effective registration statement on Form F-3 (Registration Statement No. 333-255089). H.C. Wainwright...

Digital 2024: Global social media users pass 5 billion milestone

Written by Customer Service on January 31, 2024. Posted in Public Companies.

New report finds that the world averaged 8.4 new social media users per second over the past year SAN FRANCISCO, Jan. 30, 2024 (GLOBE NEWSWIRE) — Meltwater, a global leader in media, social and consumer intelligence, and We Are Social, the socially-led creative agency, have released Digital 2024, their latest annual report on social media and digital trends worldwide. In a year full of digital milestones, Digital 2024 shows that active social media user identities* have passed the 5 billion mark (5.04 billion), equivalent to 62.3 percent of the world’s population. The global total increased by 266 million over the past year – an annual growth of 5.6 percent. The typical social media user now spends 2 hours and 23 minutes per day on their social platforms of choice, and uses 6.7 platforms each month. TikTok has the highest...

Vaxcyte Announces Pricing of $750 Million Public Offering

Written by Customer Service on January 31, 2024. Posted in Public Companies.

SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $750.0 million,...

Immunocore Prices Upsized Convertible Senior Notes Offering

Written by Customer Service on January 31, 2024. Posted in Public Companies.

Immunocore Prices Upsized Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, January 30, 2024) Immunocore Holdings plc (Nasdaq: IMCR) today announced the pricing of $350.0 million aggregate principal amount of 2.50% convertible senior notes due 2030 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Immunocore also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $52.5 million aggregate principal amount of the notes. The sale of the notes is expected to close on February 2, 2024, subject to the satisfaction of customary closing conditions....

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Written by Customer Service on January 31, 2024. Posted in Public Companies.

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2023 held on January 30, 2024 (the “Meeting”). A total of 5,375,071 common shares of the Company (the “Common Shares”) were voted, representing 33.63% of the Company’s issued and outstanding Common Shares. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of the re-appointment of MNP LLP as auditors of the Company for the ensuing year and authorizing the directors to...

Day: January 31, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice